Patent classifications
A61K31/498
USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE
The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject’s height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selective FGFR inhibitor to the subject. An example of an FGRF inhibitor used in the methods described herein is erdafitinib.
USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE
The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject’s height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selective FGFR inhibitor to the subject. An example of an FGRF inhibitor used in the methods described herein is erdafitinib.
Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.
Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR
An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided
CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY
Provided herein are compositions and methods for the treatment and prevention of cadherin-11 (CDH11) related diseases. The compositions include CDH11 inhibitors that are formulated for use in combination with chemotherapy and/or immunotherapy, to treat or prevent cancer, fibrosis, and autoimmune diseases.
CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY
Provided herein are compositions and methods for the treatment and prevention of cadherin-11 (CDH11) related diseases. The compositions include CDH11 inhibitors that are formulated for use in combination with chemotherapy and/or immunotherapy, to treat or prevent cancer, fibrosis, and autoimmune diseases.
Compounds useful as inhibitors of helios protein
Disclosed are compounds of Formula (I): ##STR00001##
or a salt thereof, wherein: Z is CR.sub.6R.sub.6 or C═O; Ring A is: ##STR00002##
and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.